Oncorus Initiates P-I Study of ONCR-177 in Patients with Advanced/ Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid Tumors
Shots:
- Oncorus has initiated a P-I study assessing ONCR-177 as monothx. and in combination with Merck’s Keytruda in patients with advanced and/or refractory cutaneous- subcutaneous or metastatic nodal solid tumors
- The P-I study enrolls ~21 cancer patients while P-II study enrolls patients to histology- specific expansion cohorts. The P-I study will evaluate the safety and tolerability and determine the recommended P-II dose and as preliminary anti-tumor activity of ONCR-177 as monothx. & combination therapy
- The planned expansion cohorts will include patients with BC- SCCHN- and melanoma. ONCR-177 is an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy and is armed with oHSV- IL-12- CCL4- FLT3LG- anti-PD-1 and anti-CTLA-4 designed to stimulate multiple arms of the immune system
Ref: Oncorus | Image: Pitt Innovation System
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com